Résumé
During the last decade, biomarkers have played an increasingly important role in the development of novel targeted cancer therapies. Since such treatments are rarely effective in all patients, predictive biomarkers to identify those most likely to benefit from a specific therapy are useful. Identification of biomarkers may also improve our understanding of how treatments work, as well as resistance mechanisms, and thus be used not only to anticipate clinical benefit but also the toxicity of a candidate drug. This applies similarly to the identification of immunological biomarkers associated with immunotherapies. The objective of such immunomonitoring is to identify prognostic but also predictive immune biomarkers in patients. Today, reliable identification of biomarkers is a necessary step to personalized treatment for cancer patients. An evaluation of the immune profile and/or the molecular profile of the tumor is expected to optimize the treatment for a better chance of therapeutic benefit. This can also apply to pediatric tumors. Here we will describe the main immunological biomarkers that have been described in patients with pediatric tumor.
langue originale | Anglais |
---|---|
titre | Immunotherapy for Pediatric Malignancies |
Editeur | Springer International Publishing |
Pages | 259-273 |
Nombre de pages | 15 |
ISBN (Electronique) | 9783319434865 |
ISBN (imprimé) | 9783319434841 |
Les DOIs | |
état | Publié - 1 janv. 2017 |